These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 9788259)
1. c-Met expression of thyroid tissue with special reference to papillary carcinoma. Oyama T; Ichimura E; Sano T; Kashiwabara K; Fukuda T; Nakajima T Pathol Int; 1998 Oct; 48(10):763-8. PubMed ID: 9788259 [TBL] [Abstract][Full Text] [Related]
2. Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Trovato M; Villari D; Bartolone L; Spinella S; Simone A; Violi MA; Trimarchi F; Batolo D; Benvenga S Thyroid; 1998 Feb; 8(2):125-31. PubMed ID: 9510120 [TBL] [Abstract][Full Text] [Related]
3. Immunostaining for Met/HGF receptor may be useful to identify malignancies in thyroid lesions classified suspicious at fine-needle aspiration biopsy. Ippolito A; Vella V; La Rosa GL; Pellegriti G; Vigneri R; Belfiore A Thyroid; 2001 Aug; 11(8):783-7. PubMed ID: 11525273 [TBL] [Abstract][Full Text] [Related]
4. Distinctive expression of STAT3 in papillary thyroid carcinomas and a subset of follicular adenomas. Trovato M; Grosso M; Vitarelli E; Ruggeri RM; Alesci S; Trimarchi F; Barresi G; Benvenga S Histol Histopathol; 2003 Apr; 18(2):393-9. PubMed ID: 12647789 [TBL] [Abstract][Full Text] [Related]
5. Difference in patterns of Met expression in papillary thyroid carcinomas and nonneoplastic thyroid tissue. Fluge Ø ; Haugen DR; Lillehaug JR; Varhaug JE World J Surg; 2001 May; 25(5):623-31. PubMed ID: 11369990 [TBL] [Abstract][Full Text] [Related]
7. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. Ruco LP; Stoppacciaro A; Ballarini F; Prat M; Scarpino S J Pathol; 2001 May; 194(1):4-8. PubMed ID: 11329134 [TBL] [Abstract][Full Text] [Related]
8. Negative/low expression of the Met/hepatocyte growth factor receptor identifies papillary thyroid carcinomas with high risk of distant metastases. Belfiore A; Gangemi P; Costantino A; Russo G; Santonocito GM; Ippolito O; Di Renzo MF; Comoglio P; Fiumara A; Vigneri R J Clin Endocrinol Metab; 1997 Jul; 82(7):2322-8. PubMed ID: 9215314 [TBL] [Abstract][Full Text] [Related]
9. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization. Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603 [TBL] [Abstract][Full Text] [Related]
10. Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Ramirez R; Hsu D; Patel A; Fenton C; Dinauer C; Tuttle RM; Francis GL Clin Endocrinol (Oxf); 2000 Nov; 53(5):635-44. PubMed ID: 11106926 [TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications. Omar E; Madhavan M; Othman NH Pathology; 2004 Apr; 36(2):152-9. PubMed ID: 15203751 [TBL] [Abstract][Full Text] [Related]
12. The expression and role of serum response factor in papillary carcinoma of the thyroid. Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551 [TBL] [Abstract][Full Text] [Related]
13. MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. Bièche I; Ruffet E; Zweibaum A; Vildé F; Lidereau R; Franc B Thyroid; 1997 Oct; 7(5):725-31. PubMed ID: 9349575 [TBL] [Abstract][Full Text] [Related]
14. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters. Lam AK; Montone KT; Nolan KA; Livolsi VA Hum Pathol; 1998 Jun; 29(6):565-8. PubMed ID: 9635675 [TBL] [Abstract][Full Text] [Related]
15. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications. Miettinen M; Kovatich AJ; Kärkkäinen P Virchows Arch; 1997 Dec; 431(6):407-13. PubMed ID: 9428928 [TBL] [Abstract][Full Text] [Related]
16. NDRG1 protein overexpression in malignant thyroid neoplasms. Gerhard R; Nonogaki S; Fregnani JH; Soares FA; Nagai MA Clinics (Sao Paulo); 2010 Jun; 65(8):757-62. PubMed ID: 20835551 [TBL] [Abstract][Full Text] [Related]
17. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Chen BK; Ohtsuki Y; Furihata M; Takeuchi T; Iwata J; Liang SB; Sonobe H Pathol Res Pract; 1999; 195(6):427-33. PubMed ID: 10399184 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma. Koo BS; Kim JM; Seo ST; Yoon YH; Kwon KR; Kim SH; Kwon HW; Bae WJ; Lim YC Ann Surg Oncol; 2014 Jul; 21(7):2310-7. PubMed ID: 24562934 [TBL] [Abstract][Full Text] [Related]
19. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042 [TBL] [Abstract][Full Text] [Related]
20. ret/PTC expression may be associated with local invasion of thyroid papillary carcinoma. Miki H; Kitaichi M; Masuda E; Komaki K; Yamamoto Y; Monden Y J Surg Oncol; 1999 Jun; 71(2):76-81; discussion 81-2. PubMed ID: 10389862 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]